

STANFORD'S REVIEW OF THE 61ST ANNUAL

AMERICAN SOCIETY OF HEMATOLOGY MEETING

Saturday, February 15, 2020 • 7:30 am – 4:45 pm The Ritz-Carlton, Half Moon Bay, CA





FACULTY

All faculty members are from Stanford University School of Medicine unless otherwise noted.

COURSE DIRECTORS

Jason Gotlib, MD, MS

Professor of Medicine, Hematology

Michaela Liedtke, MD

Associate Professor of Medicine, Hematology

STANFORD FACULTY

Ranjana Advani, MD

Saul A. Rosenberg Professor of Lymphoma, Stanford Cancer Institute

Caroline Berube, MD

Clinical Associate Professor of Medicine, Hematology Medical Director, Oral Anticoagulation Clinic

May Chien, MD

4:40 - 4:45 pm

Instructor, Pediatrics - Hematology & Oncology

Steven Coutre, MD

Professor of Medicine, Hematology Director of Hematology Clinic

Jason Gotlib, MD

Professor of Medicine, Hematology

Peter Greenberg, MD

Professor of Medicine, Hematology, Emeritus

Marie Hollenhorst, MD, PhD

Clinical Instructor, Pathology

David Iberri, MD

Clinical Assistant Professor of Medicine, Hematology

Lawrence Leung, MD

Maureen Lyles D'Ambrogio Professor in the School of Medicine, Senior Associate Dean, Veteran Affairs

Michaela Liedtke, MD

Associate Professor of Medicine, Hematology

Ravi Majeti, MD, PhD

Professor of Medicine, Hematology, Chief, Division of Hematology

Gabriel Mannis, MD

Assistant Professor of Medicine, Hematology

William Shomali, MD

Postdoctoral Medical Fellow, Hematology

Brent Tan, MD

Clinical Associate Professor, Pathology, Medical Director, Clinical Laboratory Informatics

Gerlinde Wernig, MD


Assistant Professor of Pathology

James Zehnder, MD

Professor Pathology and of Medicine, Hematology Director of Clinical Pathology, Department of Pathology



8:45 – 9:15 am	Myelodysplastic Syndromes (MDS) • Peter Greenberg, MD	
9:15 – 9:45 am	Acute Myeloid Leukemia (AML) • Gabriel Mannis, MD	
9:45 – 9:55 am	Q&A Session • Peter Greenberg, MD and Gabriel Mannis, MD	
9:55 – 10:15 am	Break	
10:15 – 11:15 am	Non-Malignant Hematology Case-Based Panel Discussion With Q&A Marie Hollenhorst, MD, PhD and May Chien, MD (Moderators), Caroline Berube, MD, and Lawrence Leung, MD	
11:15 – 11:35 am	Focus on New Drug Approvals • TBD	
11:35 am – 12:00 pm	Monoclonal Gammopathies of Clinical Significance • David Iberri, MD	
12:00 – 1:00 pm	Lunch	
1:00 – 1:45 pm	Molecular Hematopathology Tumor Board William Shomali, MD (Moderator), Gerlinde Wernig, MD, PhD, Brent Tan, MD, and James Zehnder, MD	
1:45 – 2:15 pm	Multiple Myeloma (MM) • Michaela Liedtke, MD	
2:15 – 2:45 pm	Myeloproliferative Neoplasms (MPN) • Jason Gotlib, MD, MS	
2:45 – 2:55 pm	Q&A Session • Jason Gotlib, MD, MS and Michaela Liedtke, MD	
2:55 – 3:15 pm	Break	
3:15 – 3:45 pm	Chronic Lymphocytic Leukemia (CLL) • Steven Coutre, MD	
3:45 – 4:30 pm	Hodgkin and Non-Hodgkin Lymphomas • <i>Ranjana Advani</i> , <i>MD</i>	
4:30 – 4:40 pm	Q&A Session • Ranjana Advani, MD and Steven Coutre, MD	



Closing Remarks • Michaela Liedtke, MD

STATEMENT OF NEED

The 2020 Stanford Review of the 61st Annual ASH Conference will highlight cutting-edge research and data on hematologic disorders presented at the conference, as well as provide participants with updated treatment algorithms and strategies for optimizing the care of their patients. The symposium will utilize a variety of learning modalities, including case studies, panel discussions, and audience response questions, to facilitate meaningful interactions between expert faculty presenters and symposium participants.

TARGET AUDIENCE

This is a local/regional conference designed to meet the educational needs of Hematologists, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists and Allied Health Professionals who care for patients with benign and malignant hematologic diseases.

ACCREDITATION

The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Stanford University School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California Board of Registered Nursing recognizes that Continuing Medical Education (CME) is acceptable for meeting RN continuing education requirements as long as the course is certified for *AMA PRA Category 1 Credit*™ (rn.ca.gov). Nurses will receive a Certificate of Participation following this activity that may be used for license renewal.

FACULTY DISCLOSURE

The Stanford University School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This CME activity is supported in part by educational grants. A complete list of commercial supporters will be published in the course syllabus.

LEARNING OBJECTIVES

- Evaluate the use of new chemotherapeutics and biologic regimens in subpopulations of acute myeloid leukemia patients based on patient clinical and genetic profiles and treatment goals
- · Apply treatment strategies that optimally utilize JAK inhibitors and other novel agents in patients with myeloproliferative neoplasms (MPN) and
- Evaluate optimal sequencing and combinations of novel biologicals for
- Update the application and interpretation of minimal residual disease (MRD) testing in hematologic malignancies, including AML, myeloma, and CLL
- Incorporate available therapeutic options for patients with low- or high-risk my elodysplastic syndromes and utilize the revised international prognostic scoring system (IPSS-R) with new mutation data to classify patients for treatment
- Determine the best combination regimens, novel agents, and new antibody therapies for different populations of newly diagnosed and relapsed/refractory myeloma patients, including patients who are transplant eligible and transplant ineligible
- Evaluate the results of phase II/III trials in Hodgkin and non-Hodgkin lymphomas
- Evaluate the latest efficacy and safety data for use of direct oral anticoagulants for patients with non-malignant hematology indications as well as cancer patients with thrombosis
- Use a case-based tumor-board approach to illustrate how clinical presentation, histopathology, and molecular diagnostics can be used to inform diagnosis, prognosis, and treatment of patients with blood disorders
- Review new drug approvals for patients with non-malignant and malignant hematology indications, highlighting approved indications, key efficacy

REGISTRATION Fee includes course materials, certificate of participation, breakfast and lunch.

Register online with Visa or Master Card at stanford.cloud-cme.com/hematology2020 If you prefer to pay by check or need assistance, please call (650) 497-8554 or email stanfordcme@stanford.edu. Be sure to register with an email address that you check frequently. Your email address is used for critical information, including registration confirmation, evaluation, and certificate.

ATTENDEE TYPE	FEE
Physicians, Nurses & Allied Health Professionals	\$195

CANCELLATION POLICY

Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to stanfordcme@stanford.edu.

Stanford University School of Medicine reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

CONTACT INFORMATION

For questions about the symposium, please contact Melissa Schwartz, Compliance and Meeting Planning Specialist at (650) 724-2288 or melissa.schwartz@stanford.edu

Stanford Center for Continuing Medical Education 1520 Page Mill Road, Palo Alto, CA 94304 Phone: (650) 497-8554 • Fax: (650) 497-8585

Email: stanfordcme@stanford.edu • Web: cme.stanford.edu

ACCESSIBILITY STATEMENT

Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

CONFERENCE LOCATION

Ritz-Carlton, Half Moon Bay 1 Miramontes Point Road, Half Moon Bay, CA 94109 (650) 712-7000 ritzcarlton.com/en/hotels/california/half-moon-bay



ACCOMMODATIONS

A block of rooms has been reserved at a reduced rate at the Ritz-Carlton, Half Moon Bay for conference participants on a first-come, first-served basis and may sell out before January 14, 2020. After this date, reservations will be accepted on a space available basis and at regular resort rates.

ROOM TYPE	RATE
Run of Resort	\$450*

*Plus Taxes, California Tourism Fee, and Resort Fees per night.

To make room reservations:

- Visit book.passkey.com/go/StanfordHematology2020
- Call the hotel directly at 1-888-293-0524

To receive the group rate, please mention Stanford's Review of the 61st Annual American Society of Hematology Meeting.

A Continuing Medical Education Conference presented by the Department of Medicine, Division of Hematology at the Stanford University School of Medicine. Sponsored by the Stanford University School of Medicine